New drug may speed wound healing for rare blistering skin conditions
NCT ID NCT07011589
First seen May 08, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests whether the drug efgartigimod (VYVGART) can help people with two rare blistering skin diseases—recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)—by lowering harmful antibodies that attack the skin. About 18 participants aged 12 and older will receive the drug through an IV, and some will also get a gene therapy gel (VYJUVEK) on wounds. The goal is to see if wounds heal faster and quality of life improves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Redwood City, California, 94163, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.